Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab

Authors:	Sudha Visvanathan Patrick Baum Richard Vinisko Ramona Schmid Mary Flack Bojan Lalovic Oliver Kleiner Judilyn Fuentes-Duculan Sandra Garcet Justin W. Davis Kristie M. Grebe Jay S. Fine Steven J. Padula James G. Krueger

Affiliation:	1. Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn;2. Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany;3. Laboratory for Investigative Dermatology, Rockefeller University, New York, NY;4. AbbVie, North Chicago, Ill;5. AbbVie, Worcester, Mass;6. Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

Abstract:

Keywords:	Corresponding author: Sudha Visvanathan, PhD, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Rd, Ridgefield, CT 06877. Risankizumab ustekinumab IL-23 IL-12 IL-17 psoriasis biomarkers BLIMP-1 B lymphocyte-induced maturation protein-1 BSA Body surface area DC Dendritic cell DC-LAMP Dendritic cell lysosome-associated membrane glycoprotein DEG Differentially expressed gene FDR False discovery rate IL-17R IL-17 receptor LCN Lipocalin PASI Psoriasis Area and Severity Index RHE Reconstructed human epidermal RNA-seq RNA sequencing
本文献已被 ScienceDirect 等数据库收录！